• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.8803 -0.0364 (-3.97%)
Streaming Delayed Price Updated: 9:52 AM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
June 22, 2026
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
June 16, 2026
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 03, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗
June 03, 2026
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers. 
Via Benzinga
News headline image
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 22, 2026
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
May 05, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 04, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 04, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
April 10, 2026
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $3 Million Public Offering
April 02, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
April 01, 2026
Via Chartmill
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
March 31, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
March 31, 2026
Via Chartmill
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
March 31, 2026
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
March 31, 2026
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
March 31, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
March 25, 2026
Via Chartmill
News headline image
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
Reverse Split Expected to Take Effect March 30, 2026 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
News headline image
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
March 12, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
March 05, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
March 02, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the BIO Investment & Growth Summit
February 26, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap